WO2008108549A1 - Method on long-term structural preservation of hemocyte utilizing cellular lyophilization technique - Google Patents
Method on long-term structural preservation of hemocyte utilizing cellular lyophilization technique Download PDFInfo
- Publication number
- WO2008108549A1 WO2008108549A1 PCT/KR2008/001119 KR2008001119W WO2008108549A1 WO 2008108549 A1 WO2008108549 A1 WO 2008108549A1 KR 2008001119 W KR2008001119 W KR 2008001119W WO 2008108549 A1 WO2008108549 A1 WO 2008108549A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- concentration
- hemocytes
- cell
- trehalose
- hours
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 45
- 210000003677 hemocyte Anatomy 0.000 title claims abstract description 16
- 230000007774 longterm Effects 0.000 title claims abstract description 15
- 238000004321 preservation Methods 0.000 title claims description 7
- 238000004108 freeze drying Methods 0.000 title abstract description 12
- 230000001413 cellular effect Effects 0.000 title description 3
- 229940000351 hemocyte Drugs 0.000 title description 2
- 210000004027 cell Anatomy 0.000 claims abstract description 73
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims abstract description 51
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims abstract description 51
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims abstract description 51
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 45
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 claims abstract description 34
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 28
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 28
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 claims abstract description 17
- GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 claims abstract description 17
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 claims abstract description 17
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims abstract description 17
- 235000010389 delta-tocopherol Nutrition 0.000 claims abstract description 17
- 235000019136 lipoic acid Nutrition 0.000 claims abstract description 17
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229960003987 melatonin Drugs 0.000 claims abstract description 17
- 229960002663 thioctic acid Drugs 0.000 claims abstract description 17
- 239000002446 δ-tocopherol Substances 0.000 claims abstract description 17
- 102000004877 Insulin Human genes 0.000 claims abstract description 15
- 108090001061 Insulin Proteins 0.000 claims abstract description 15
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims abstract description 15
- 235000000069 L-ascorbic acid Nutrition 0.000 claims abstract description 15
- 239000002211 L-ascorbic acid Substances 0.000 claims abstract description 14
- 229960005070 ascorbic acid Drugs 0.000 claims abstract description 14
- 229940125396 insulin Drugs 0.000 claims abstract description 14
- 239000000872 buffer Substances 0.000 claims abstract description 13
- 241000282414 Homo sapiens Species 0.000 claims abstract description 10
- 210000003743 erythrocyte Anatomy 0.000 claims description 46
- 206010018910 Haemolysis Diseases 0.000 claims description 18
- 230000008588 hemolysis Effects 0.000 claims description 18
- 150000003180 prostaglandins Chemical class 0.000 claims description 5
- 239000000463 material Substances 0.000 abstract description 31
- 238000005534 hematocrit Methods 0.000 abstract description 7
- 238000001035 drying Methods 0.000 abstract description 5
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 abstract 1
- 229960000711 alprostadil Drugs 0.000 abstract 1
- 239000007853 buffer solution Substances 0.000 abstract 1
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 abstract 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 abstract 1
- 239000000523 sample Substances 0.000 abstract 1
- 230000006641 stabilisation Effects 0.000 abstract 1
- 238000011105 stabilization Methods 0.000 abstract 1
- 238000002474 experimental method Methods 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 210000003527 eukaryotic cell Anatomy 0.000 description 12
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000003963 antioxidant agent Substances 0.000 description 9
- 235000006708 antioxidants Nutrition 0.000 description 9
- 230000003078 antioxidant effect Effects 0.000 description 7
- 210000000170 cell membrane Anatomy 0.000 description 7
- 239000006285 cell suspension Substances 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 229960005322 streptomycin Drugs 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Natural products CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 102000001554 Hemoglobins Human genes 0.000 description 5
- 108010054147 Hemoglobins Proteins 0.000 description 5
- 210000000601 blood cell Anatomy 0.000 description 5
- 230000005779 cell damage Effects 0.000 description 5
- 208000037887 cell injury Diseases 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000002949 hemolytic effect Effects 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 229930024421 Adenine Natural products 0.000 description 3
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 229960000643 adenine Drugs 0.000 description 3
- RJGDLRCDCYRQOQ-UHFFFAOYSA-N anthrone Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3CC2=C1 RJGDLRCDCYRQOQ-UHFFFAOYSA-N 0.000 description 3
- 150000002016 disaccharides Chemical class 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000003223 protective agent Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000005034 decoration Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 2
- 210000001723 extracellular space Anatomy 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000008303 genetic mechanism Effects 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229940056360 penicillin g Drugs 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000012224 working solution Substances 0.000 description 2
- 241000233866 Fungi Species 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 1
- 239000007836 KH2PO4 Substances 0.000 description 1
- 150000000996 L-ascorbic acids Chemical class 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229940050526 hydroxyethylstarch Drugs 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0641—Erythrocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/32—Amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/36—Lipids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/33—Insulin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/80—Neurotransmitters; Neurohormones
- C12N2501/825—Serotonine (5-HT); Melatonine
Definitions
- the field of this invention belongs under cell preservation using lyophilization technique. If this method is utilized for preservation of eukaryotic cell, lyophilized cell can be stabilized structurally and can be preserved without cell damage over a long period of time.
- Method related with this study is to load high treahlose level in the extracellular space and then to increases trehalose concentration of cell inside.
- This method has advantage that cell membrane is not manipulated artificially. But there is a problem that cell damage increases because of high treahalose level in itself. If erythrocjtes are incubated during 24 hours, the half degree of the cells become hemolytic. This hemolytic erythrocyte should be removed one by one to use clinically, but this technique is very difficult. Moreover non-hemolytic erythrocyte can not be regarded healthy for its weakness. So using this method, technique that stabilze the cell and cell membrane should be developed.
- Vacuum condition can do protection of microoiganisms by minimizing oxidation, but there are a problems in case that preserve eukaryotic cell; it is impossible to make high vacuum condition that gas does not exist totally, the minimum gas induce eukaryotic cell to cell oxidation because eukaryotic cell don't have genetic mechanism that stoping cellular function in the dehydrated state. This oxidation produce free radical, it destroys cell oiganelle and cell membrane. Method that solve this problem is to find the stable materials for preserving eukaryotic cell. Disclosure of Invention Technical Problem
- the first subject that should solve is as following. When cells are loaded with trehalose of high concentration, cell damage should be reduced to clinical usable level. To use clinically, next two conditions must be satisfied; First, The rate of cell damage must become around 5%. Second, trehalose concentration of cell inside must become more than 6OmM. It is not difficult to make cell model loaded to high trehalose level. Simply trehalose and antioxidant have only to be put on the incubated cells. But it is very difficult that determinate concentration and preparation of trehalose and antioxidant. Several kinds of antioxidant must be put on one by one and observe result one after another. Previous our study revealed that insulin increased antioxidant function on hemolysis of red blood cell. So, mixture of antioxidant and insulin were loaded on the same cell model.
- glycerol is selected among several materials.
- Third, water absorptiveness of glycerol is very high, but if there does not exits water in storage receptacle, there will be no circumstance to absorb water. And glycerol exits liquid state in room temperature. Fourth, glycerol is very low toxicity and low cell permeability. Fifth, glycerol has no explosiveness, and there is no any change of state in room temperature.
- the model of cells to preserve is human erythrocytes.
- the antioxidants are selected all materials including with ⁇ -tocopherol, ⁇ -lipoic acid, melatonin, N- acetyl-L-cysteine, L-ascorbic acid which is good effect from previous hemolysis experiment. Insulin is used as material which rises an effect of antioxidant.
- PBS Phosphate-buffered saline, 300mOsm, pH 7.2
- ADSOL (4ffim ⁇ sm) contained 11 ImM glucose, 2mM adenine, 154mM NaCl and 4ImM mannitol.
- Buffer PBS(T) contained PBS and indicated amount of trehalose.
- Buffer ADSOL(T) contained ADSOL and K-phosphate and indicated amount of trehalose.
- ADSOL(T) (80OmM) contained 80OmM endotoxin- free trehalose (Hayashibara biochemical lab.
- ⁇ - tocopherol was prepared as aqueous solution including l%(v/v) ethanol.
- ⁇ -lipoic acid and melatonin was prepared as aqueous solution including 0.5%(v/v) ethanol. This use of ethanol did not show no significant change in previous study of red blood cell hemolysis. Order of experiments, measuring methods, results of experiment were as followings
- erythrocytes were collected from the bottom portion of the packed red cells. Then the cells were washed in PBS and centrifuged at 515g, lOmin three times. At each spin, erythrocytes were collected same method. Finally the erythrocytes were stored in PBS at 4 0 C with 30% hematocrit and used within 1 day.
- the loaded cells (0.5ml 30% hematocrit) were centrifugated at 350g for 3min and were mixed with 4ml of 80% methanol. The mixture was incubated at 85 0 C for 45min followed by centrifugation at 20Og for lOmin. The supernatant was collected and evaporated using a vacuum centrifuge(Labconco, USA), and dry residue was dissolved in 3mL of nano-pure water. This sample (3mL) were mixed with 6mL of anthrone reagent [2% anthrone in concentrated sulfuric acid], heated to 100 0 C for 3min, and allowed to cool.
- anthrone reagent 2% anthrone in concentrated sulfuric acid
- Absorbance at 620nm was measured on a spectrophotometer (Hitachi U2000, Japan)at room temperature and compared with a standard curve. Since the anthrone method detects all sugars, unloaded control erythrocytes were always treated in parallel. These values, normalized for cell count, were subtracted from the trehalose specifically and to avoid artifact due to endogenous sugars. Data are shown for at least three independent experiments.
- Figure 1 presents the result of incubated erythrocytes in 80OmM trehalose buffer without cell protection protocol for 15 hours in 37 0 C.
- erythrocytes were incubated during 15 hours ( ⁇ +4. ImM)
- this result showed that trehalose concentration of cell interior becomed above 6OmM.
- Figure 2 presents degree of erythrocytes hemolysis in 80OmM trehalose buffer without cell protection protocol in 37 0 C.
- erythrocytes were incubated for 15 hours(25 ⁇ 3.1%), erythrocytes showed 25% hemolysis.
- This result showed that erythrocytes were available to use clinically if only hemolytic erythrocytes were removed.
- this result showed that 5% hemolysis happened when 3 hours passed. Therefore, cell protection protocol must decrease cell damage up to result of 3 hours hemolysis statistically.
- Figure 3 presents the degree of hemolysis under each conditions. A(5.2+0.69%) and
- Figure 4 presents the result of incubated erythrocytes in 80OmM trehalose buffer with the final cell protection protocol ( ⁇ - tocopherol, ⁇ - lipoic acid, melatonin, N- acetyl-L-cysteine, L-ascorbic acid, insulin) in 37 0 C. It showed that concentration of cell inside beconed above 6OmM when erythrocytes were incubated for 15 hours (68+3.ImM). This value showed that there was no statistical significance to compared to value of result which was incubated for 15 hours (69+4.ImM) in Figure 1.
- the model of cells to preserve is human hemocytes.
- the names and concentration of cell protection material are 5 x 10 '4 M L-ascorbic acid, 5 x 10 '5 M ⁇ -lipoic acid, 5 x 10 ⁇ 5 M Melatonin, 3 x 10 4 M N-acetyl-L-cysteine, 10 5 M ⁇ -tocopherol, and 5 x 10 5 M insulin.
- the 10 5 M prostaglandin El is also used because prostaglandin El did role of stabilizing platelet in our previous experiment.
- PBS Phosphate-buffered saline, 300mOsm, pH 7.2
- ADSOL 462mOsm
- ADSOL contained 11 ImM glucose, 2mM adenine, 154mM NaCl and 4ImM mannitol.
- Buffer PBS(T) contained PBS and indicated amount of trehalose.
- Buffer ADSOL(T) contained ADSOL and K-phosphate and indicated amount of trehalose.
- ADSOL(T) (80OmM) contained 80OmM endotoxin-free trehalose (Hayashibara biochemical lab.
- Lyophilizing buffer contained lOOmOsmol ADSOL(24mM glucose, 0.43mM adenine, 33mM NaCl, 89mM mannitol), 10OmM trehalose, 66mM K-phosphate, 15% high molecular weight hydroxyethyl starch (HES, B. Braun Medical, Irvine, CA) and 2.5% human serum albumin (HSA, Sigma- Aldrich).
- ⁇ -tocopherol was prepared as aqueous solution including l%(v/v) ethanol.
- ⁇ -lipoic acid, melatonin and prostaglandin were prepared as aqueous solution including 0.5%(v/v) ethanol.
- erythrocytes were collected from the bottom portion of the packed red cells, leukocytes were collected from the buffy coat, and platelets were collected from upper layer of sample. Each hemocytes were collected to same tube. Then the cells were washed in PBS and centrifuged at 515g, lOmin three times. At each spin, blood corpuscles were collected same method. Washed erythrocytes were stored in PBS at 4 0 C with 30% hematocrit and used within 1 day.
- lyophilizer (Labconco,USA) The conditions of lyophilizer (Labconco,USA) were set as following. Hemocytes were incubated for 15 hours and were added with lyophilization buffer until the hematocrit reached to 5%. Then, the hemocytes were cooled at a rate of I 0 C per minute until they got to -4O 0 C, in which temperature the hemocytes were incubated for 30 minutes. Primary drying were performed at -3O 0 C for 7 hours at a vacuum of 30mTorr. During secondary drying which were performed for 6 hours, shelf temperature were increased from -3O 0 C to 2O 0 C at a rate of 0.8 0 C per minute using a vacuum of SOmTorr. After then, samples were put into a specially manufactured container. The air in the container were removed and the container were filled with anhydrous glycerol(>99.5%) for a long-term storage.
- Fig 5 presents well-preserved erythrocytes generally as time passes with little damage of erythrocytes. For the 6 months, cell morphology was showed most well- preserved aspect. Also, because there is no living things that live in the anhydrous glycerol(>99.5%), if basic aseptic method is performed, the contamination to mi- crooiganism, fungus, virus will be not concerned about. However, there are some problem that totally recover function. This problem is next subject that must solve. [41] Fig 6 presents sample that be utilized for remembering deceased people in funeral.
- the decoration container have lyophilized erythrocytes of the deceased. Even if all of deceased disappears with death, his blood corpuscle cells will be kept over a long period of time. After this is utilized for funeral ceremony, keeping can be with family or deceased.
- Fig 7 presents sample that be utilized for commemoration between lovers.
- the decoration container is personal ornaments which is portable commemoration material of lover.
- Figure 1 shows a graph illustraing the change of trehalose level at intervals of 3 hours when to erythrocytes were added with 80OmM trehalose in 37 0 C.
- Figure 2 shows a graph illustraing the degree of hemolysis at intervals of 3 hours when to erythrocytes were added with 80OmM trehalose in 37 0 C.
- Figure 3 shows a graph illustrating the degree of hemolysis occurred in 15 hours observation depending on each situation of cell protection protocols when to erythrocytes were added with 80OmM trehalose in 37 0 C.
- Figure 4 shows a graph illustrating the change of trehalose level at intervals of 3 hours observation depending on final cell protection protocols when to erythrocytes were added with 80OmM trehalose in 37 0 C.
- Figure 5 shows the result of long-term storage of lyophilized cells observed depending on time under the phase contrast microscope.
- Figure 6 shows a sample of lyophilized cells stored using this technique which can be utilized for rememberig deceased people.
- Figure 7 shows a sample of lyophilized cells stored using this technique which can be utilized for commemoration between lovers.
- T3 3 hours, T ⁇ 6 hours, T9: 9 hours, T12 12 hours, T15: 15 hours
- C The condition that erythrocytes were added with 80OmM trehalose, 5 x 10 4 M L- ascorbic acid for 15 hours in 37 0 C.
- D The condition that erythrocytes were added with 80OmM trehalose, 5 x 10 5 M ⁇ - lipoic acid for 15 hours in 37 0 C.
- E The condition that erythrocytes were added with 80OmM trehalose, 5 x 10 5 M
- F The condition that erythrocytes were added with 80OmM trehalose, 3 x 10 4 M N- acetyl-L-cysteine for 15 hours in 37 0 C.
- G The condition that erythrocytes were added with 80OmM trehalose, 10 5 M ⁇ - tocopherol for 15 hours.
- H The condition that erythrocytes were added with 80OmM trehalose, 5 x 10 4 M L- ascorbic acid, 5 x 10 5 M ⁇ -lipoic acid, 5 x 10 5 M Melatonin, 3 x 10 4 M N- acetyl-L-cysteine, 10 '5 M ⁇ -tocopherol for 15 hours in 37 0 C.
- the lyophilized cell can be preserved for remembering deceased people in funeral.
- the lyophilized cell can be preserved for remembering deceased people in funeral.
- the lyophilized cell can be preserved for commemoration between lovers.
Abstract
This invention was made on the method of preserving cells structurally for a short or long time using lyophilization technique. The technique to preserve lyophilized cells of human for a long time has its limitation, but our research institution has found a way to preserve lyophilized cells structurally and safely for a short and long time. The model of cells to preserve is human hemocytes. Explanations will be given on the method of storing in two categories: short-term storage and long-term storage. To preserve hemocytes safely for a short time, hemocytes is incubated in 800mM trehalose buffer solution at 37°C for 15 hours. The names and concentration of cell protection material are 5 × 10-4M L-ascorbic acid, 5 × 10-5M α-lipoic acid, 5 ×× 10-5M Melatonin, 3 × 10-4M N-acetyl-L-cysteine, 10-5M δ-tocopherol, 5 × 10-5M insulin, and 10-5M prostaglandin E1. Long-term storage starts with lyophilization of incubated hemocytes, which will be added with glycerol later. Hemocytes will be incubated for 15 hours and will be added with lyophilization buffer until the hematocrit reaches to 5%. Then, the hemocytes will be cooled at a rate of 1? per minute until they get to -40?, in which temperature the hemocytes will be incubated for 30 minutes. Primary drying will be performed at -30? for 7 hours at a vacuum of 30mTorr. During secondary drying which will be performed for 6 hours, shelf temperature will be increased from -30? to 20? at a rate of 0.8? per minute using a vacuum of 50mTorr. After then, samples will be put into a specially manufactured container. The air in the container will be removed and the container will be filled with anhydrous glycerol(≥99.5%) for a long-term storage. Though a lot of studies are required to perfectly recover the function, this method ensures structural stabilization which enables semi-permanent storage. This technique to store lyophilized cells semi-permanently can be utilized in many ways in our daily lives. For example, for remembering deceased people in funeral or for commemoration between lovers. Despite various purposes in our lives, this technique has never been developed. Thus, we apply for a patent on the method and utilization of this technique.
Description
Description
METHOD ON LONG-TERM STRUCTURAL PRESERVATION OF HEMOCYTE UTILIZING CELLULAR LYOPHILIZATION
TECHNIQUE
Technical Field
[1] The field of this invention belongs under cell preservation using lyophilization technique. If this method is utilized for preservation of eukaryotic cell, lyophilized cell can be stabilized structurally and can be preserved without cell damage over a long period of time. Background Art
[2] When the cell is dehydrated, cell loses the structural and functional water. What kind of material is necessary to protect cell from this situation. This material must substitutes water roles and it should be stabilized cell membrane. This material must substitute structural water of the cell. And this material must maintain the stability of enzymatic activity in the various oiganelle of the cell inside. This material has been selected as trehalose in this experiment. Trehalose is discovered from the microbe or the plant of part in the dehydrated environment. But eukaryotic cell will not be able to keep the cell long time with only trehalose. The following is its reason. First of all, it is difficult to load trehalose without damage of cell membrane in the eukaryotic cells, because trehalose does not go through the cell membrane in usual condition. The major challenge in using disaccharide for preservation of cells is to overcome the impermeable plasma membranes to these sugars and then to introduce the disaccharide at a sufficiently high intracellular concentration. Several experimental approaches have been developed for introducing disaccharide into mammalian cells; experiments introduced trehalose by endocytosis, experiments introduced trehalose by dimethyl sulfoxide during the transition, experiments introduce trehalose by genetically engineered pore-forming protein, experiments introduced trehalose by genetically engineered mammalian cell line, experiments intruded trehalose by high trehalose level in the extracellular space. Each methods are the merits and demerits. Method related with this study is to load high treahlose level in the extracellular space and then to increases trehalose concentration of cell inside. This method has advantage that cell membrane is not manipulated artificially. But there is a problem that cell damage increases because of high treahalose level in itself. If erythrocjtes are incubated during
24 hours, the half degree of the cells become hemolytic. This hemolytic erythrocyte should be removed one by one to use clinically, but this technique is very difficult. Moreover non-hemolytic erythrocyte can not be regarded healthy for its weakness. So using this method, technique that stabilze the cell and cell membrane should be developed.
[3] Next, the following subject is concerning problem which is happened when red blood cell be preserved during long term. Our previous study found out that damage of eu- karyotic cell in high trehalose level was similar to damage by lacking of antioxidant or by excessive oxidation. So our laboratory presumed that the reasons which were not preserved long term were following two reasons; damage of cell oiganelle by free radical and natural dischaige of biological eneigy. That is, eukaryotic cells do not have protective genetic mechanism under dehydrated state, compared to some mi- crooiganisms endurable to dehydrated circumstances. In order to preserve the cells in the receptacle for long duration, usual method is used that make the inside of the receptacle vacuum condition. Vacuum condition can do protection of microoiganisms by minimizing oxidation, but there are a problems in case that preserve eukaryotic cell; it is impossible to make high vacuum condition that gas does not exist totally, the minimum gas induce eukaryotic cell to cell oxidation because eukaryotic cell don't have genetic mechanism that stoping cellular function in the dehydrated state. This oxidation produce free radical, it destroys cell oiganelle and cell membrane. Method that solve this problem is to find the stable materials for preserving eukaryotic cell. Disclosure of Invention Technical Problem
[4] The first subject that should solve is as following. When cells are loaded with trehalose of high concentration, cell damage should be reduced to clinical usable level. To use clinically, next two conditions must be satisfied; First, The rate of cell damage must become around 5%. Second, trehalose concentration of cell inside must become more than 6OmM. It is not difficult to make cell model loaded to high trehalose level. Simply trehalose and antioxidant have only to be put on the incubated cells. But it is very difficult that determinate concentration and preparation of trehalose and antioxidant. Several kinds of antioxidant must be put on one by one and observe result one after another. Previous our study revealed that insulin increased antioxidant function on hemolysis of red blood cell. So, mixture of antioxidant and insulin were loaded on the same cell model.
[5] Next second subject that should solve is as following. What kind of material can stabilize structurally eukaryotic cell and keep long term to be. This material must possess following conditions. First, the reaction of this material must be reversible. If this material has permanent binding to cell oiganelle, cell can not do cellular activity more. Second, this material has a role of freeze drying protective agent. If this material has freeze drying protective effect, it will have more desired effect than vacuum preservation. Third, this material has little water. Because freeze drying cell has about 5% water, this material must have similar water content. Fourth, this material should be low toxicity and less cell permeability. Fifth, this material must be safe. That is, this material has no explosiveness or no change by room temperature.
[6] In this study, glycerol is selected among several materials. First, glycerol is material that exist in human body. Glycerol is main component of triglyceride and phospholipid and used biological eneigy by glucose syithesis. Therefore this material has reversible reaction with human cell. Second, glycerol is freeze drying protective agent. Glycerol is used much by freeze drying protective agent next to trehalose in the natural. Third, water absorptiveness of glycerol is very high, but if there does not exits water in storage receptacle, there will be no circumstance to absorb water. And glycerol exits liquid state in room temperature. Fourth, glycerol is very low toxicity and low cell permeability. Fifth, glycerol has no explosiveness, and there is no any change of state in room temperature. Technical Solution
[7] Solution of first subject
[8] The model of cells to preserve is human erythrocytes. The antioxidants are selected all materials including with δ-tocopherol, α-lipoic acid, melatonin, N- acetyl-L-cysteine, L-ascorbic acid which is good effect from previous hemolysis experiment. Insulin is used as material which rises an effect of antioxidant. PBS (Phosphate-buffered saline, 300mOsm, pH 7.2) contained 154mM NaCl, 1.06mM KH2 PO 4 and 5.6mM Na2HPO4 ADSOL (4ffimθsm) contained 11 ImM glucose, 2mM adenine, 154mM NaCl and 4ImM mannitol. Buffer PBS(T) contained PBS and indicated amount of trehalose. Buffer ADSOL(T) contained ADSOL and K-phosphate and indicated amount of trehalose. ADSOL(T) (80OmM) contained 80OmM endotoxin- free trehalose (Hayashibara biochemical lab. Japan) and lOOmOsm ADSOL. δ- tocopherol was prepared as aqueous solution including l%(v/v) ethanol. α-lipoic acid and melatonin was prepared as aqueous solution including 0.5%(v/v) ethanol. This use of ethanol did not show no significant change in previous study of red blood cell
hemolysis. Order of experiments, measuring methods, results of experiment were as followings
[9] 1. order of experiments
[10] ® Whole human blood was drawn the same day from healthy volunteer.
[11] © This whole blood was gathered to tube with EDTA(ethylenediaminetetraacetate).
[12] © Whole blood was separated to each blood corpuscle by centrifugation (329g,
14min). After spin, erythrocytes were collected from the bottom portion of the packed red cells. Then the cells were washed in PBS and centrifuged at 515g, lOmin three times. At each spin, erythrocytes were collected same method. Finally the erythrocytes were stored in PBS at 40C with 30% hematocrit and used within 1 day.
[13] ® At beginning experiment, the cell washed in ADSOL(T) (800mM)and centrifuged at 515g, lOmin three times. At each spin, erythrocytes were collected same method with 30% hematocrit.
[14] © Then some of cell suspension were put to Erlenmeyer flask, time was checked and each conditions were experimented. The suspension was set as used buffer was ADSOL(T) (80OmM), temperature was 370C, time was 15hours and cell protective materials were antioxidants and insulin combination in accordance with protocol. Concentrations of all materials were final concentrations of cell suspension.
[15] © All incubations contained 10 /i^penicillin-streptomycin/m^ cell suspension to vitiate any microbial growth during the overnight incubations. The working solution of penicillin- streptomycin contained 300mg penicillin G and 500 mg streptomycin in 10ml buffer.
[16] 2. methods of trehalose detection
[17] Following incubation, erythrocytes were washed three times in 900mOsm PBS
(which is isoosmotic to the loading medium) and collected by centrifugation(1960g, lmin). The loaded cells (0.5ml 30% hematocrit) were centrifugated at 350g for 3min and were mixed with 4ml of 80% methanol. The mixture was incubated at 850C for 45min followed by centrifugation at 20Og for lOmin. The supernatant was collected and evaporated using a vacuum centrifuge(Labconco, USA), and dry residue was dissolved in 3mL of nano-pure water. This sample (3mL) were mixed with 6mL of anthrone reagent [2% anthrone in concentrated sulfuric acid], heated to 1000C for 3min, and allowed to cool. Absorbance at 620nm was measured on a spectrophotometer (Hitachi U2000, Japan)at room temperature and compared with a standard curve. Since the anthrone method detects all sugars, unloaded control erythrocytes were always treated in parallel. These values, normalized for cell count, were
subtracted from the trehalose specifically and to avoid artifact due to endogenous sugars. Data are shown for at least three independent experiments.
[18] 3. Hemolysis determination
[19] Loaded erythrocytes were analyzed for RBC number, cell volume, mean corpuscular hemoglobin, and total hemoglobin using a Bechman Coulter Counter(Act Diff, USA). Percent hemolysis was determined by measuring the hemoglobin(Hb) content in the cell suspension (total Hb) and in the supernatant(free Hb) after pelleting the cells by centrifugation (196Og, lmin for isolated and loaded erythrocytes). Total hemoglobin was converted to cyanmethemoglobin using by Drabkin's reagent and the absorbance was measuring at 54Onm. The percent hemolysis was calculated using the following formula.
[20] % Hemolysis = 100 x (OD 540 of the supernatant)/(OD540 of total hemoglobin)
[21] 4. Statistics
[22] All chemicals were purchased from Sigma Chemical Co.(St.Louis, MO) unless otherwise noted. Data were analyzed statistically using Wilcoxon (n=5). A P value of less than 0.05 was considered significant.
[23] 5. Results
[24] Figure 1 presents the result of incubated erythrocytes in 80OmM trehalose buffer without cell protection protocol for 15 hours in 370C. When erythrocytes were incubated during 15 hours (©+4. ImM), this result showed that trehalose concentration of cell interior becomed above 6OmM.
[25] Figure 2 presents degree of erythrocytes hemolysis in 80OmM trehalose buffer without cell protection protocol in 370C. When erythrocytes were incubated for 15 hours(25±3.1%), erythrocytes showed 25% hemolysis. This result showed that erythrocytes were available to use clinically if only hemolytic erythrocytes were removed. Also, this result showed that 5% hemolysis happened when 3 hours passed. Therefore, cell protection protocol must decrease cell damage up to result of 3 hours hemolysis statistically.
[26] Figure 3 presents the degree of hemolysis under each conditions. A(5.2+0.69%) and
1(5.0+0.59%) showed no statistical significance, other case showed statistical significance. H(66±1.17%) case showed that hemolysis approached to 5% level. Its case had cell protection protocol consisted of δ - tocopherol, α - lipoic acid, melatonin, N- acetyl-L-cysteine, L-ascorbic acid. I case showed that hemolysis approximate nearly to 5% level. Its had cell protection protocol consisted of 105M δ - tocopherol, 5 x 105M α - lipoic acid, 5 x 105M Melatonin, 5 x 104M L-ascorbic acids, 3 x 104M N-
acetyl-L-cysteine, and 5 x 10 5M insulins. This result showed that δ - tocopherol, α- lipoic acid, melatonin, N-acetyl-L-cysteine, L-ascorbic acid, insulin were very effective cell protection protocol.
[27] Figure 4 presents the result of incubated erythrocytes in 80OmM trehalose buffer with the final cell protection protocol (δ - tocopherol, α - lipoic acid, melatonin, N- acetyl-L-cysteine, L-ascorbic acid, insulin) in 370C. It showed that concentration of cell inside beconed above 6OmM when erythrocytes were incubated for 15 hours (68+3.ImM). This value showed that there was no statistical significance to compared to value of result which was incubated for 15 hours (69+4.ImM) in Figure 1.
[28] Therefore, final setting values of conditions are requisite that names of cell protection protocol are δ - tocopherol, α - lipoic acid, melatonin, N-acetyl-L-cysteine, L-ascorbic acid, insulin, incubated time is 15hours, and incubated temperature is 370C.
[29] Solution of second subject
[30] The model of cells to preserve is human hemocytes. The names and concentration of cell protection material are 5 x 10'4M L-ascorbic acid, 5 x 10'5M α-lipoic acid, 5 x 10~5 M Melatonin, 3 x 104M N-acetyl-L-cysteine, 10 5M δ-tocopherol, and 5 x 105M insulin. And the 105M prostaglandin El is also used because prostaglandin El did role of stabilizing platelet in our previous experiment. PBS (Phosphate-buffered saline, 300mOsm, pH 7.2) contained 154mM NaCl, 1.06mM KH2PO4 and 5.6mM Na2HPO4 ADSOL (462mOsm) contained 11 ImM glucose, 2mM adenine, 154mM NaCl and 4ImM mannitol. Buffer PBS(T) contained PBS and indicated amount of trehalose. Buffer ADSOL(T) contained ADSOL and K-phosphate and indicated amount of trehalose. ADSOL(T) (80OmM) contained 80OmM endotoxin-free trehalose (Hayashibara biochemical lab. Japan) and lOOmOsm ADSOL. Lyophilizing buffer contained lOOmOsmol ADSOL(24mM glucose, 0.43mM adenine, 33mM NaCl, 89mM mannitol), 10OmM trehalose, 66mM K-phosphate, 15% high molecular weight hydroxyethyl starch (HES, B. Braun Medical, Irvine, CA) and 2.5% human serum albumin (HSA, Sigma- Aldrich). δ-tocopherol was prepared as aqueous solution including l%(v/v) ethanol. α-lipoic acid, melatonin and prostaglandin were prepared as aqueous solution including 0.5%(v/v) ethanol. This use of ethanol did not show no significant change in previous study of red blood cell hemolysis. All incubations contained 10 /^penicillin-streptomycin/ mi cell suspension to vitiate any microbial growth during the overnight incubations. The working solution of penicillin- streptomycin contained 300mg penicillin G and 500 mg streptomycin in 10ml buffer. Order and results of experiments are as followings.
[31] 1. order of experiments
[32] ® Whole human blood was drawn the same day from healthy volunteer.
[33] © This whole blood was gathered to tube with EDTA(ethylenediaminetetraacetate).
[34] © Whole blood was separated to each blood corpuscle by centrifugation (329g,
14min). After spin, erythrocytes were collected from the bottom portion of the packed red cells, leukocytes were collected from the buffy coat, and platelets were collected from upper layer of sample. Each hemocytes were collected to same tube. Then the cells were washed in PBS and centrifuged at 515g, lOmin three times. At each spin, blood corpuscles were collected same method. Washed erythrocytes were stored in PBS at 40C with 30% hematocrit and used within 1 day.
[35] ® At beginning experiment, the cell washed in ADSOL(T) (800mM)and centrifuged at 515g, lOmin three times. At each spin, blood corpuscles were collected same method and washed erythrocytes were set with 30% hematocrit.
[36] © Then some of cell suspension were put to Erlenmeyer flask. Then cell protection materials were put to flask. The suspension were set as used buffer was ADSOL(T) (80OmM), temperature was 37, time was 15 hours. Concentrations of all materials were final concentrations of cell suspension.
[37] © The conditions of lyophilizer (Labconco,USA) were set as following. Hemocytes were incubated for 15 hours and were added with lyophilization buffer until the hematocrit reached to 5%. Then, the hemocytes were cooled at a rate of I0C per minute until they got to -4O0C, in which temperature the hemocytes were incubated for 30 minutes. Primary drying were performed at -3O0C for 7 hours at a vacuum of 30mTorr. During secondary drying which were performed for 6 hours, shelf temperature were increased from -3O0C to 2O0C at a rate of 0.80C per minute using a vacuum of SOmTorr. After then, samples were put into a specially manufactured container. The air in the container were removed and the container were filled with anhydrous glycerol(>99.5%) for a long-term storage.
[38] © The verification of result was observed by phase difference microscope(Meiji techno., Japan). Observation of slide was done under rehydrated state.
[39] 2. Results
[40] Fig 5 presents well-preserved erythrocytes generally as time passes with little damage of erythrocytes. For the 6 months, cell morphology was showed most well- preserved aspect. Also, because there is no living things that live in the anhydrous glycerol(>99.5%), if basic aseptic method is performed, the contamination to mi- crooiganism, fungus, virus will be not concerned about. However, there are some
problem that totally recover function. This problem is next subject that must solve. [41] Fig 6 presents sample that be utilized for remembering deceased people in funeral.
The decoration container have lyophilized erythrocytes of the deceased. Even if all of deceased disappears with death, his blood corpuscle cells will be kept over a long period of time. After this is utilized for funeral ceremony, keeping can be with family or deceased. [42] Fig 7 presents sample that be utilized for commemoration between lovers. The decoration container is personal ornaments which is portable commemoration material of lover.
Advantageous Effects
[43] 1. One possibility is presented that eukaryotic cell can be preserved long term by lyophilized technique.
[44] 2. This experimental result is presented with one of protocol when eukaryotic cell is lyophilized.
[45] 3. It is found that combination of several cell protective materials are more useful than single specific material.
[46] 4. This result can be regarded as the data of the foundation when lyophilized eukaryotic cell will be done perfect functional revival after long term storage. Brief Description of the Drawings
[47] Figure 1 shows a graph illustraing the change of trehalose level at intervals of 3 hours when to erythrocytes were added with 80OmM trehalose in 370C.
[48] Figure 2 shows a graph illustraing the degree of hemolysis at intervals of 3 hours when to erythrocytes were added with 80OmM trehalose in 370C.
[49] Figure 3 shows a graph illustrating the degree of hemolysis occurred in 15 hours observation depending on each situation of cell protection protocols when to erythrocytes were added with 80OmM trehalose in 370C.
[50] Figure 4 shows a graph illustrating the change of trehalose level at intervals of 3 hours observation depending on final cell protection protocols when to erythrocytes were added with 80OmM trehalose in 370C.
[51] Figure 5 shows the result of long-term storage of lyophilized cells observed depending on time under the phase contrast microscope.
[52] Figure 6 shows a sample of lyophilized cells stored using this technique which can be utilized for rememberig deceased people.
[53] Figure 7 shows a sample of lyophilized cells stored using this technique which can
be utilized for commemoration between lovers. [54] Keys to Abbreviations in the Figure
[55] T3: 3 hours, Tά 6 hours, T9: 9 hours, T12 12 hours, T15: 15 hours
[56] A: The condition that erythrocytes were added with 80OmM trehalose for 3 hours in
370C. [57] B: The condition that erythrocytes were added with 80OmM trehalose for 15 hours in
370C. [58] C: The condition that erythrocytes were added with 80OmM trehalose, 5 x 10 4M L- ascorbic acid for 15 hours in 370C. [59] D: The condition that erythrocytes were added with 80OmM trehalose, 5 x 10 5M α- lipoic acid for 15 hours in 370C. [60] E: The condition that erythrocytes were added with 80OmM trehalose, 5 x 10 5M
Melatonin for 15 hours in 370C. [61] F: The condition that erythrocytes were added with 80OmM trehalose, 3 x 10 4M N- acetyl-L-cysteine for 15 hours in 370C. [62] G: The condition that erythrocytes were added with 80OmM trehalose, 10 5M δ- tocopherol for 15 hours. [63] H: The condition that erythrocytes were added with 80OmM trehalose, 5 x 10 4M L- ascorbic acid, 5 x 105M α-lipoic acid, 5 x 105M Melatonin, 3 x 104M N- acetyl-L-cysteine, 10'5M δ-tocopherol for 15 hours in 370C. [64] I: The condition that erythrocytes were added with 80OmM trehalose, 5 x 10 4M L- ascorbic acid, 5 x 105M α-lipoic acid, 5 x 105M Melatonin, 3 x 104M N- acetyl-L-cysteine, 10 5M δ-tocopherol, and 5 x 105M insulin for 15 hours in 370C.
Best Mode for Carrying Out the Invention [65] The lyophilized cell can be preserved for remembering deceased people in funeral.
Mode for the Invention
[66] The lyophilized cell can be preserved for remembering deceased people in funeral.
[67] The lyophilized cell can be preserved for commemoration between lovers.
Industrial Applicability [68] Though this method is utilized for memory of deceased or commemoration of lover now, but in future, freezing drying method will be substitute for deep freezing method which is required high cost by advance of this method.
Claims
[1] Method of cultivating erythrocytes by compositively using L-ascorbic acid, α- lipoic acid, melatonin, N-acetyl-L-cysteine, δ-tocopherol and insulin to reduce the hemolysis of the erythrocytes, when imposing trehalose to the cells.
[2] In claim 1, method to hold the concentration of above L-ascorbic acid as 5 x I0 4
M, the concentration of α-lipoic acid as 5 x 105M, the concentration of melatonin as 5 x 10'5M, the concentration of N-acetyl-L-cysteine as 3 x 10'4M, the concentration of δ-tocopherol 105M and the concentration of insulin as 5 x 10'5M.
[3] In both of claim 1 and 2, method with a feature of cell cultivating temperature of
370C.
[4] Method to utilize the lyophilized cells which were produced to preserve for a long term, in the concrete to be used as remembrance and commemoration .
[5] In claim 4, method to store human hemocytes for a long term and method with a feature of long term preservation with glycerol after lyophilizing the cells by using L-ascorbic acid, α-lipoic acid, melatonin, N-acetyl-L-cysteine, δ- tocopherol, insulin and prostaglandin El with trehalose buffer as cell protecting protocol.
[6] In claim 5, method with a feature with trehalose concentration of 80OmM, the concentration of L-ascorbic acid as 5 x 104M, the concentration of α-lipoic acid as 5 x 105M, the concentration of melatonin as 5 x 105M, the concentration of N-acetyl-L-cysteine as 3 x 10'4M , the concentration of δ-tocopherol as 105M, the concentration of insulin as 5 x 105M, the concentration of prostaglandin El as 105M, and glycerol of 99.5% in an absolute state.
[7] In claim 5 and 6, method with a feature which cultivates the hemocytes at 370C.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070021350A KR100868602B1 (en) | 2007-03-05 | 2007-03-05 | Method that minimize cell hemolysis in human red blood cells exposed to high trehalose levels |
KR10-2007-0021350 | 2007-03-05 | ||
KR1020070023828A KR20080083376A (en) | 2007-03-12 | 2007-03-12 | Method that human blood cells keep long term structurally utilizing cellular lyophilization technique |
KR10-2007-0023828 | 2007-03-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008108549A1 true WO2008108549A1 (en) | 2008-09-12 |
Family
ID=39738397
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2008/001119 WO2008108549A1 (en) | 2007-03-05 | 2008-02-27 | Method on long-term structural preservation of hemocyte utilizing cellular lyophilization technique |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2008108549A1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013087936A1 (en) * | 2011-12-16 | 2013-06-20 | Galderma Research & Development | Combination of a prostaglandin receptor agonist and an mc1r receptor agonist for the treatment and/or prevention of pigmentation disorders |
WO2015191633A1 (en) * | 2014-06-10 | 2015-12-17 | Biomatrica, Inc. | Stabilization of non-denatured polypeptides, nucleic acids, and exosomes in a blood sample at ambient temperatures |
US9376709B2 (en) | 2010-07-26 | 2016-06-28 | Biomatrica, Inc. | Compositions for stabilizing DNA and RNA in blood and other biological samples during shipping and storage at ambient temperatures |
US9725703B2 (en) | 2012-12-20 | 2017-08-08 | Biomatrica, Inc. | Formulations and methods for stabilizing PCR reagents |
US9845489B2 (en) | 2010-07-26 | 2017-12-19 | Biomatrica, Inc. | Compositions for stabilizing DNA, RNA and proteins in saliva and other biological samples during shipping and storage at ambient temperatures |
US10064404B2 (en) | 2014-06-10 | 2018-09-04 | Biomatrica, Inc. | Stabilization of thrombocytes at ambient temperatures |
US10568317B2 (en) | 2015-12-08 | 2020-02-25 | Biomatrica, Inc. | Reduction of erythrocyte sedimentation rate |
US11604026B2 (en) | 2019-03-14 | 2023-03-14 | Terumo Bct Biotechnologies, Llc | Lyophilization loading tray assembly and system |
US11634257B2 (en) | 2017-10-09 | 2023-04-25 | Terumo Bct Biotechnologies, Llc | Lyophilization container and method of using same |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5242792A (en) * | 1991-02-25 | 1993-09-07 | The United States Of America As Represented By The Secretary Of The Navy | Method for the preservation of red blood cells by lyophilization using glycerol or inositol with disaccharides |
US5965438A (en) * | 1995-06-07 | 1999-10-12 | Phyton, Inc. | Cryopreservation of plant cells |
US20040067480A1 (en) * | 2002-10-04 | 2004-04-08 | Organ Recovery Systems, Inc. | Method for treatment of cellular materials with sugars prior to preservation |
-
2008
- 2008-02-27 WO PCT/KR2008/001119 patent/WO2008108549A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5242792A (en) * | 1991-02-25 | 1993-09-07 | The United States Of America As Represented By The Secretary Of The Navy | Method for the preservation of red blood cells by lyophilization using glycerol or inositol with disaccharides |
US5965438A (en) * | 1995-06-07 | 1999-10-12 | Phyton, Inc. | Cryopreservation of plant cells |
US20040067480A1 (en) * | 2002-10-04 | 2004-04-08 | Organ Recovery Systems, Inc. | Method for treatment of cellular materials with sugars prior to preservation |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9376709B2 (en) | 2010-07-26 | 2016-06-28 | Biomatrica, Inc. | Compositions for stabilizing DNA and RNA in blood and other biological samples during shipping and storage at ambient temperatures |
US9845489B2 (en) | 2010-07-26 | 2017-12-19 | Biomatrica, Inc. | Compositions for stabilizing DNA, RNA and proteins in saliva and other biological samples during shipping and storage at ambient temperatures |
US9999217B2 (en) | 2010-07-26 | 2018-06-19 | Biomatrica, Inc. | Compositions for stabilizing DNA, RNA, and proteins in blood and other biological samples during shipping and storage at ambient temperatures |
US9364455B2 (en) | 2011-12-16 | 2016-06-14 | Galderma Research & Development | Combination of a prostaglandin receptor agonist and an MC1R receptor agonist for the treatment and/or prevention of pigmentation disorders |
WO2013087936A1 (en) * | 2011-12-16 | 2013-06-20 | Galderma Research & Development | Combination of a prostaglandin receptor agonist and an mc1r receptor agonist for the treatment and/or prevention of pigmentation disorders |
US9725703B2 (en) | 2012-12-20 | 2017-08-08 | Biomatrica, Inc. | Formulations and methods for stabilizing PCR reagents |
US11672247B2 (en) | 2014-06-10 | 2023-06-13 | Biomatrica, Inc. | Stabilization of thrombocytes at ambient temperatures |
WO2015191633A1 (en) * | 2014-06-10 | 2015-12-17 | Biomatrica, Inc. | Stabilization of non-denatured polypeptides, nucleic acids, and exosomes in a blood sample at ambient temperatures |
US10064404B2 (en) | 2014-06-10 | 2018-09-04 | Biomatrica, Inc. | Stabilization of thrombocytes at ambient temperatures |
US10772319B2 (en) | 2014-06-10 | 2020-09-15 | Biomatrica, Inc. | Stabilization of thrombocytes at ambient temperatures |
US10568317B2 (en) | 2015-12-08 | 2020-02-25 | Biomatrica, Inc. | Reduction of erythrocyte sedimentation rate |
US11116205B2 (en) | 2015-12-08 | 2021-09-14 | Biomatrica, Inc. | Reduction of erythrocyte sedimentation rate |
US11634257B2 (en) | 2017-10-09 | 2023-04-25 | Terumo Bct Biotechnologies, Llc | Lyophilization container and method of using same |
US11604026B2 (en) | 2019-03-14 | 2023-03-14 | Terumo Bct Biotechnologies, Llc | Lyophilization loading tray assembly and system |
US11609042B2 (en) | 2019-03-14 | 2023-03-21 | Terumo Bct Biotechnologies, Llc | Multi-part lyophilization container and method of use |
US11609043B2 (en) | 2019-03-14 | 2023-03-21 | Terumo Bct Biotechnologies, Llc | Lyophilization container fill fixture, system and method of use |
US11740019B2 (en) | 2019-03-14 | 2023-08-29 | Terumo Bct Biotechnologies, Llc | Lyophilization loading tray assembly and system |
US11747082B2 (en) | 2019-03-14 | 2023-09-05 | Terumo Bct Biotechnologies, Llc | Multi-part lyophilization container and method of use |
US11815311B2 (en) | 2019-03-14 | 2023-11-14 | Terumo Bct Biotechnologies, Llc | Lyophilization container fill fixture, system and method of use |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008108549A1 (en) | Method on long-term structural preservation of hemocyte utilizing cellular lyophilization technique | |
JP4777908B2 (en) | Biological materials and methods and solutions for storage of biological materials | |
US6127177A (en) | Controlled reversible poration for preservation of biological materials | |
RU2396748C2 (en) | Medium for storage of cells | |
US20100105133A1 (en) | Somatic Cells for Use in Cell Therapy | |
US9642353B2 (en) | Desiccated biologics and methods of preparing the same | |
AU2009228141A1 (en) | Mehtod, system, and apparatus for hypothermic collection, storage, transport and banking of birth tissue | |
Kanias et al. | Mechanism of hemoglobin-induced cellular injury in desiccated red blood cells | |
Lin et al. | Donor heart preservation in an empty beating state under mild hypothermia | |
Nie et al. | Platelet cryopreservation using a trehalose and phosphate formulation | |
CA3115973A1 (en) | Oxygenation media for ex-vivo preservation of organs and tissues | |
KR102319110B1 (en) | Composition of cryopreservation solution for long-term storage of cellular bio drugs | |
Holovati et al. | Blood preservation workshop: New and emerging trends in research and clinical practice | |
KR101426804B1 (en) | Platelet preserving composition, and kit for preserving platelet, and method for preserving platelet using the same | |
Solheim et al. | Red cell metabolism and preservation | |
Han et al. | Non-frozen preservation of mammalian tissue using green tea polyphenolic compounds | |
Mahmud | Cryopreservation of stem cell product | |
US8802363B2 (en) | Zeodration method for the preservation of blood platelets | |
Zhou et al. | Loading trehalose into red blood cells by improved hypotonic method | |
Mittal et al. | Desiccation tolerance of adult stem cells in the presence of trehalose and glycerol | |
KR20080083376A (en) | Method that human blood cells keep long term structurally utilizing cellular lyophilization technique | |
US20050031597A1 (en) | Cells and improved method for preserving cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08723157 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08723157 Country of ref document: EP Kind code of ref document: A1 |